Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 416

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience

Hart, Phil A, Topazian, Mark D, Witzig, Thomas E, Clain, Jonathan E, Gleeson, Ferga C, Klebig, Robin R, Levy, Michael J, Pearson, Randall K, Petersen, Bret T, Smyrk, Thomas C, Sugumar, Aravind, Takahashi, Naoki, Vege, Santhi S, Chari, Suresh T·2013·Gut

Abstract

BACKGROUND: There is a paucity of data on long-term management of type 1 autoimmune pancreatitis (AIP), a relapsing steroid-responsive disorder. OBJECTIVE: We describe our experience with treatment of relapses and maintenance of remission using steroid-sparing immunomodulators (IMs) and induction of remission using rituximab (RTX). METHODS: We obtained details of disease relapse and treatment in 116 type 1 AIP patients from clinic visits, medical records and telephone interviews. We compared relapse free survival in those treated with IMs versus those treated with steroids alone, assessed patients' response to RTX, and identified treatment-related complications. RESULTS: During a median follow-up of 47 months, 52/116 AIP patients experienced 76 relapse episodes. The first relapse was treated with another course of steroids in 24 patients, and with steroids plus IM in another 27 patients; subsequent relapse-free survival until a second relapse was similar in the two groups (p=0.23). 38 patients received an IM for >2 months; failure or intolerance of IM therapy occurred in 17 (45%). 12 patients with steroid or IM intolerance/resistance were treated with RTX, an antiCD20 antibody; 10 (83%) experienced complete remission and had no relapses while on maintenance therapy. Treatment-limiting side effects related to RTX were uncommon. CONCLUSIONS: In type 1 AIP relapses are common. Relapse-free survival is similar in those treated with steroids plus IM compared to those treated with steroids alone. Nearly half the patients on IMs will relapse during treatment. RTX is effective in the treatment of both IM resistant and steroid intolerant patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2012-302886

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 416

Metadata

Authors
Hart, P. A., Topazian, M. D., Witzig, T. E., Clain, J. E., Gleeson, F. C., Klebig, R. R., Levy, M. J., Pearson, R. K., Petersen, B. T., Smyrk, T. C., Sugumar, A., Takahashi, N., Vege, S. S., & Chari, S. T.
Venue
Gut
Publisher
BMJ
Published
2012-08-30
Volume
62
Issue
11
Pages
1607-1615
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2139500303
Cited by
416
References
19
FWCI
20.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. https://app.cochat.ai/papers/10.1136/gutjnl-2012-302886
The paper
Hart, P. A., Topazian, M. D., Witzig, T. E., Clain, J. E., Gleeson, F. C., Klebig, R. R., Levy, M. J., Pearson, R. K., Petersen, B. T., Smyrk, T. C., Sugumar, A., Takahashi, N., Vege, S. S., & Chari, S. T. (2013). Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. https://doi.org/10.1136/gutjnl-2012-302886

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.